|
PT901786E
(pt)
|
1997-08-11 |
2007-08-07 |
Pfizer Prod Inc |
Disperções farmacêuticas sólidas com biodisponibilidade melhorada
|
|
JP2002512965A
(ja)
*
|
1998-04-24 |
2002-05-08 |
スカリスタ リミティッド |
鬱病の治療およびそのための薬学的調製物
|
|
HK1040055B
(zh)
*
|
1998-05-22 |
2005-04-01 |
伊莱利利公司 |
奥氮平和氟西汀在制备治疗对抗治疗的严重抑郁症的药物中的应用
|
|
US6960577B2
(en)
|
1998-05-22 |
2005-11-01 |
Eli Lilly And Company |
Combination therapy for treatment of refractory depression
|
|
BR9911068A
(pt)
*
|
1998-05-29 |
2001-02-06 |
Lilly Co Eli |
Terapia combinada para tratamento de distúrbios bipolares
|
|
AU1321900A
(en)
*
|
1998-10-23 |
2000-05-15 |
Sepracor, Inc. |
Compositions and methods employing r(-) fluoxetine and other active ingredients
|
|
CA2352611A1
(en)
*
|
1998-11-23 |
2000-06-02 |
Sepracor Inc. |
2-hydroxymethylolanzapine compositions and methods
|
|
EP1027885B1
(en)
*
|
1999-02-09 |
2008-07-09 |
Pfizer Products Inc. |
Basic drug compositions with enhanced bioavailability
|
|
US6706283B1
(en)
*
|
1999-02-10 |
2004-03-16 |
Pfizer Inc |
Controlled release by extrusion of solid amorphous dispersions of drugs
|
|
ATE311883T1
(de)
|
1999-03-12 |
2005-12-15 |
Aesica Pharmaceuticals Ltd |
Stabile pharmazeutische anwendungsform für paroxetin-anhydrat
|
|
CA2373855A1
(en)
*
|
1999-05-12 |
2000-11-23 |
Solvay Pharmaceuticals B.V. |
Method of treating psychotic disorders
|
|
JP2003500353A
(ja)
*
|
1999-05-19 |
2003-01-07 |
アストラゼネカ・アクチエボラーグ |
処置方法
|
|
AU4973800A
(en)
*
|
1999-06-09 |
2000-12-28 |
Eli Lilly And Company |
Combination for treating weight gain associated with antipsychotic use comprising an atypical antipsychotic and an h2 antagonist
|
|
AR021155A1
(es)
*
|
1999-07-08 |
2002-06-12 |
Lundbeck & Co As H |
Tratamiento de desordenes neuroticos
|
|
WO2001022941A1
(en)
*
|
1999-09-28 |
2001-04-05 |
H. Lundbeck A/S |
Melt granulated composition and modified release dosage form prepared from said composition
|
|
EP1242072A4
(en)
|
1999-12-17 |
2004-02-04 |
Bristol Myers Squibb Co |
ANTIPSYCHOTIC HETEROCYCLIC COMPOUNDS
|
|
YU43702A
(sh)
|
1999-12-23 |
2004-11-25 |
Pfizer Products Inc. |
Farmaceutske kompozicije koje obezbeđuju povećanje koncentracije leka
|
|
US6572890B2
(en)
*
|
2000-01-13 |
2003-06-03 |
Osmotica Corp. |
Osmotic device containing venlafaxine and an anti-psychotic agent
|
|
WO2002003684A2
(en)
*
|
2000-06-30 |
2002-01-10 |
Eli Lilly And Company |
Combination for treating psychoses, comprising an antipsychotic and a muscarinic agonist
|
|
US7666445B2
(en)
*
|
2000-10-20 |
2010-02-23 |
The Trustees Of The University Of Pennsylvania |
Polymer-based surgically implantable haloperidol delivery systems and methods for their production and use
|
|
US20030232881A1
(en)
*
|
2000-10-27 |
2003-12-18 |
H. Lundbeck A/S |
Crystals of pharmaceutically acceptable salts of citalopram, methods of crystallization, and pharmaceutical compositions comprising them
|
|
CA2364211A1
(en)
*
|
2000-12-05 |
2002-06-05 |
Phillip Branch Chappell |
Combination treatment for depression, anxiety and psychosis
|
|
MXPA03006003A
(es)
*
|
2001-01-02 |
2005-09-08 |
Upjohn Co |
Nuevas combinaciones de farmacos.
|
|
DE60219761T2
(de)
*
|
2001-02-06 |
2008-01-17 |
Astrazeneca Ab |
Verwendung von quetiapin für die behandlung von kokain-abhängigkeit
|
|
US20020123490A1
(en)
*
|
2001-03-01 |
2002-09-05 |
Pfizer Inc. |
Combination treatment for anxiety, depression, obsessive compulsive disorder and psychosis
|
|
CA2445843A1
(en)
*
|
2001-05-01 |
2002-11-07 |
H. Lundbeck A/S |
The use of enantiomeric pure escitalopram
|
|
US7034059B2
(en)
|
2001-07-02 |
2006-04-25 |
Sepracor Inc. |
Methods of using norfluoxetine
|
|
EP1551393A4
(en)
*
|
2002-07-30 |
2010-06-16 |
Peter Migaly |
COMBINATION OF THERAPY FOR DEPRESSION, PREVENTION OF SUICIDE AND VARIOUS MEDICAL AND PSYCHIATRIC DISORDERS
|
|
US20070077301A1
(en)
*
|
2002-12-23 |
2007-04-05 |
Meyer Glenn A |
Venlafaxine osmotic device formulation
|
|
AR042806A1
(es)
|
2002-12-27 |
2005-07-06 |
Otsuka Pharma Co Ltd |
Combinacion de derivados de carboestirilo e inhibidores de la reabsorcion de serotonina para el tratamiento de trastornos del animo
|
|
WO2004060374A1
(en)
|
2002-12-27 |
2004-07-22 |
Otsuka Pharmaceutical Co., Ltd. |
Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders
|
|
JP2007502856A
(ja)
*
|
2003-05-16 |
2007-02-15 |
ファイザー・プロダクツ・インク |
精神病性障害および抑うつ性障害の治療
|
|
EP1626722A1
(en)
*
|
2003-05-16 |
2006-02-22 |
Pfizer Products Inc. |
Method for enhancing cognition using ziprasidone
|
|
BRPI0410419A
(pt)
*
|
2003-05-16 |
2006-05-30 |
Pfizer Prod Inc |
tratamento para a ansiedade com ziprasidona
|
|
NZ527142A
(en)
*
|
2003-07-23 |
2006-03-31 |
Douglas Pharmaceuticals Ltd |
A stable suspension formulation
|
|
US20050032781A1
(en)
*
|
2003-08-06 |
2005-02-10 |
Elliot Ehrich |
Methods for administering active agents to CYP 2D6 sensitive patients
|
|
EP1547650A1
(en)
*
|
2003-12-02 |
2005-06-29 |
B & B Beheer NV |
Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
|
|
US7855195B2
(en)
|
2003-12-02 |
2010-12-21 |
Pharmaneuroboost N.V. |
Method of treating mental disorders using D4 and 5-HT2A antagonists, inverse agonists or partial agonists
|
|
US8304431B2
(en)
|
2003-12-02 |
2012-11-06 |
Pharmaneuroboost N.V. |
Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
|
|
US7884096B2
(en)
|
2003-12-02 |
2011-02-08 |
Pharmaneuroboost N.V. |
Method of treating mental disorders using of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
|
|
EP1713486A4
(en)
*
|
2003-12-02 |
2009-04-29 |
Sheldon Leslie James |
COMBINED THERAPY FOR THE TREATMENT OF DEMENTIA, DEPRESSION AND APATHY
|
|
CN1964713A
(zh)
*
|
2003-12-23 |
2007-05-16 |
达法尔摩公司 |
多巴胺－受体结合化合物的共同使用
|
|
KR101242486B1
(ko)
*
|
2004-01-12 |
2013-03-13 |
더 트러스티스 오브 더 유니버시티 오브 펜실베니아 |
장기 전달을 위한 제형 및 그의 이용 방법
|
|
US8221778B2
(en)
|
2005-01-12 |
2012-07-17 |
The Trustees Of The University Of Pennsylvania |
Drug-containing implants and methods of use thereof
|
|
US20050171088A1
(en)
*
|
2004-01-30 |
2005-08-04 |
Astrazeneca Ab |
Treatment of psychoses with dibenzothiazepine antipsychotic
|
|
ES2303462B1
(es)
|
2004-09-06 |
2009-06-05 |
Shasun Chemicals And Drugs Limited |
Nuevo procedimiento para la preparacion de una forma polimorfica i de olanzapina farmaceuticamente pura.
|
|
WO2006083204A1
(en)
*
|
2004-12-27 |
2006-08-10 |
Alpha 2 Pharmaceutical Ab |
Antidepressant medicament comprising idazoxan and a selective serotonin reuptake inhibitor
|
|
CZ200563A3
(cs)
*
|
2005-02-02 |
2006-10-11 |
Zentiva, A. S. |
Lécivý prípravek obsahující jako úcinnou slozku olanzapin a zpusob jeho výroby
|
|
UA97349C2
(uk)
*
|
2005-09-08 |
2012-02-10 |
Х. Луннбэк А/С |
Стійкі тверді склади сертиндолу
|
|
US20070093471A1
(en)
*
|
2005-10-26 |
2007-04-26 |
Alamo Pharmaceuticals, Llc |
Compositions and methods for the administration clozapine formulations which modulate body weight
|
|
CA2677623C
(en)
*
|
2007-02-09 |
2015-04-07 |
Alphapharm Pty Ltd |
A dosage form containing two or more active pharmaceutical ingredients in different physical forms
|
|
WO2008122019A1
(en)
*
|
2007-04-02 |
2008-10-09 |
Cypress Biosciences, Inc. |
Improving the tolerability of both mirtazapine and reboxetine by using them in combination
|
|
US8198305B2
(en)
*
|
2007-04-13 |
2012-06-12 |
Concert Pharmaceuticals Inc. |
1,2-benzisoxazol-3-yl compounds
|
|
RU2508106C2
(ru)
*
|
2007-08-01 |
2014-02-27 |
Сергей Олегович Бачурин |
Способы и композиции для лечения шизофрении с использованием атипичной нейролептической комбинированной терапии
|
|
RU2508096C2
(ru)
*
|
2007-08-01 |
2014-02-27 |
Сергей Олегович Бачурин |
Способы и композиции для лечения шизофрении с использованием нейролептической комбинированной терапии
|
|
ES2653852T3
(es)
*
|
2007-08-03 |
2018-02-09 |
Richter Gedeon Nyrt. |
Composiciones farmacéuticas que contienen ligandos del receptor de dopamina y procedimientos de tratamiento usando ligandos del receptor de dopamina
|
|
EP2240173A4
(en)
*
|
2008-01-25 |
2013-07-17 |
Alphapharm Pty Ltd |
PHARMACEUTICAL COMPOSITION OF DULOXETINE WITH DELAYED RELEASE
|
|
WO2011018801A2
(en)
*
|
2009-08-12 |
2011-02-17 |
Genepharm India Pvt Ltd |
Solid oral dosage form of ziprasidone
|
|
JP2013510176A
(ja)
|
2009-11-06 |
2013-03-21 |
ピエール ファーブル メディカモン |
（１ｓ，２ｒ）−２−（アミノメチル）−ｎ，ｎ−ジエチル−１−フェニルシクロプロパンカルボキサミドの新規結晶形態
|
|
US10154988B2
(en)
|
2012-11-14 |
2018-12-18 |
The Johns Hopkins University |
Methods and compositions for treating schizophrenia
|
|
WO2015089494A1
(en)
*
|
2013-12-13 |
2015-06-18 |
Ankenman Ralph |
Compositions and methods for treating dysregulated systems
|
|
US9782398B2
(en)
*
|
2014-02-07 |
2017-10-10 |
Neurocrine Biosciences, Inc. |
Pharmaceutical compositions comprising an antipsychotic drug and a VMAT2 inhibitor and uses thereof
|
|
DK3368534T3
(da)
|
2015-10-30 |
2021-02-15 |
Neurocrine Biosciences Inc |
Valbenazin-ditosylat og polymorfer deraf
|
|
DK3394057T3
(da)
|
2015-12-23 |
2022-04-11 |
Neurocrine Biosciences Inc |
Syntetisk fremgangsmåde til fremstilling af (S)-(2R,3R,11BR)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11B-hexahydro-1H-pyrido[2,1,-A]isoquinolin-2-yl 2-amino-3-methylbutanoat-di(4-methylbenzensulfonat)
|
|
US10336679B2
(en)
*
|
2016-10-24 |
2019-07-02 |
Syneurx International (Taiwan) Corp. |
Polymorphic forms of sodium benzoate and uses thereof
|
|
KR20230170136A
(ko)
|
2017-01-27 |
2023-12-18 |
뉴로크린 바이오사이언시즈 인코퍼레이티드 |
특정 vmat2 억제제의 투여 방법
|
|
CA3076000A1
(en)
|
2017-09-21 |
2019-03-28 |
Neurocrine Biosciences, Inc. |
High dosage valbenazine formulation and compositions, methods, and kits related thereto
|
|
US20200230127A1
(en)
|
2017-10-10 |
2020-07-23 |
Neurocrine Biosciences, Inc. |
Methods for the Administration of Certain VMAT2 Inhibitors
|
|
KR20250070134A
(ko)
|
2017-10-10 |
2025-05-20 |
뉴로크린 바이오사이언시즈 인코퍼레이티드 |
특정 vmat2 억제제의 투여 방법
|
|
SG11202100303QA
(en)
|
2018-08-15 |
2021-02-25 |
Neurocrine Biosciences Inc |
Methods for the administration of certain vmat2 inhibitors
|
|
CN108926569A
(zh)
*
|
2018-08-24 |
2018-12-04 |
山西医科大学第医院 |
一种非典型抗精神病药物组合物
|
|
CN108938635A
(zh)
*
|
2018-08-24 |
2018-12-07 |
山西医科大学第医院 |
一种低剂量非典型抗精神病药物组合物
|
|
CN108938645A
(zh)
*
|
2018-08-24 |
2018-12-07 |
山西医科大学第医院 |
一种抗精神病药物组合物
|
|
US10940141B1
(en)
|
2019-08-23 |
2021-03-09 |
Neurocrine Biosciences, Inc. |
Methods for the administration of certain VMAT2 inhibitors
|
|
CN111084778B
(zh)
*
|
2019-12-31 |
2022-06-24 |
北京鑫开元医药科技有限公司 |
一种奥氮平盐酸氟西汀胶囊及其制备方法
|